New Horizons in the Management of Sickle Cell Disease (SCD): What Managed Care Needs to
Know About Novel Therapies

A continuing medical education activity sponsored by NAMCP and AAMCN.

This activity is an archive from the live session from the live webinars held on December 12
and December 14, 2018. If you participated in the live session, you are not eligible for
continuing education credits from this archive.

This activity is valid from January 1, 2019 to December 31, 2020

Instructions for CME/CNE: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.

 

Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This presentation is supported by an educational grant from
Novartis Pharmaceuticals

Description:
Sickle cell disease (SCD) is a hereditary blood disorder characterized by sickle-shaped red blood cells. It is a chronic, life-long, debilitating disease with many forms that can range in clinical severity from asymptomatic to life-threatening. In the US, SCD affects an estimated 90,000 to 100,000 Americans. Acute sickle cell pain crises, also referred to as vaso-occlusive crises, are a common painful complication of the disease and the main reason that patients seek medical care in hospitals. Currently, treatment options are limited. Several novel therapies are currently undergoing late stage clinical trials or regulatory review for SCD which will likely dramatically change the treatment paradigm. This webinar program on integrating emerging therapies into the treatment paradigm will address these novel treatment options, emerging value equations, the limitations of current treatment options, and recent clinical research on new agents to optimize the management of patients with SCD.

Upon completion of this activity, participants will be able to:

  • Discuss the pathophysiology, physical manifestations, economic burden, clinical course, and impact on patient quality of life of sickle cell disease (SCD)

  • Examine the safety and efficacy of emerging therapies that manage acute vaso-occlusive pain events in SCD

  • Assess approaches currently utilized by third party payers to manage costs associated with the care of patients with SCD

  • Explore strategies to manage treatment-related adverse events of emerging therapies in the management of SCD

  • Discuss the managed care considerations of novel therapies by exploring where these agents may fit into current SCD management paradigm
     

Faculty: Gary Owens, MD
President
Gary Owens Associates

Disclosure:

Dr. Owens has no relevant financial information to disclose. His presentation has been peer reviewed for any bias.
  Planning Committee:
Bill Williams, MD has no relevant financial relationships to disclose.
Jeremy Williams has no relevant financial relationships to disclose.
Will Williams has no relevant financial relationships to disclose.
Jacqueline Cole, RN, MS, CMCN has no relevant financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
The National Association of Managed Care Physicians (NAMCP) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category I creditsTM.

The American Association of Managed Care Nurses (AAMCN) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation (ANCC).

Nurses who complete this activity and achieve a passing score will receive 1 hour in continuing
nursing credit.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hour toward CMCN recertification requirements.

This presentation is supported by an educational grant from
Novartis Pharmaceuticals

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue